基于“邪伏肠络”理论探讨结直肠炎癌转化的动态演变机制及治疗思路
Dynamic Evolution Mechanisms and Therapeutic Strategies of Colorectal Inflammation-Cancer Transformation Based on “Pathogen Latent in Intestinal Collaterals” Theory
DOI: 10.12677/tcm.2026.1510546, PDF,   
作者: 夏雨桐:成都中医药大学临床医学院,四川 成都;成都中医药大学附属医院普外科,四川 成都;王 敏*:成都中医药大学附属医院普外科,四川 成都
关键词: 邪伏肠络;结直肠炎癌转化;动态演变;炎症性肠病;络病理论;中西医结合;Pathogen Latent in Intestinal Collaterals; Colorectal Inflammation-Cancer Transformation; Dynamic Evolution; Inflammatory Bowel Disease; Collateral Disease Theory; Integrated Traditional Chinese and Western Medicine
摘要: 结直肠炎癌转化是炎症性肠病迁延不愈进展为结直肠癌的核心病理过程,也是临床防治结直肠癌的关键窗口期,现代医学对其干预仍存在靶点单一、不良反应多、远期防治效果有限等局限。“邪伏肠络”理论源于中医伏邪学说与络病理论的融合,精准契合结直肠炎癌转化隐匿起病、缠绵难愈、渐进恶变的病理特点。本文系统梳理“邪伏肠络”的理论渊源与核心内涵,将其与脾虚、湿热、血瘀等传统核心病机进行比较辨析,阐释“邪伏肠络”理论的学术优势与不可替代性。基于该理论阐释结直肠三期动态演变机制,对应提出分阶段治疗思路,并结合炎癌转化不同阶段探讨中西医结合治疗的可行路径与中医治疗定位,以期为中医药防治结直肠炎癌转化提供新的理论视角与临床实践指导。
Abstract: Colorectal inflammation-cancer transformation is the core pathological process through which inflammatory bowel disease (IBD) progresses into colorectal cancer due to persistent and intractable inflammation, and it also represents a critical window period for the clinical prevention and treatment of colorectal cancer. However, modern medical interventions for this process still face limitations such as single target selection, numerous adverse reactions, and limited long-term prevention and treatment efficacy. The theory of “Pathogen Latent in Intestinal Collaterals” originates from the integration of the TCM theory of latent pathogenic factors and collateral disease theory, and it accurately aligns with the pathological characteristics of colorectal inflammation-cancer transformation, including insidious onset, lingering and intractable course, and progressive malignant transformation. This paper systematically sorts out the theoretical origin and core connotation of “Pathogen Latent in Intestinal Collaterals”, compares and analyzes it with traditional core pathogenesis such as spleen deficiency, dampness-heat and blood stasis, and expounds the academic advantages and irreplaceability of this theory. On this basis, the three-stage dynamic evolution mechanism of colorectal cancer is expounded, stage-specific therapeutic strategies are proposed, and the feasible paths of integrated traditional Chinese and Western medicine treatment and the positioning of TCM therapy at different stages of inflammation-cancer transformation are discussed, aiming to provide new theoretical perspectives and clinical practice guidance for TCM prevention and treatment of colorectal inflammation-cancer transformation.
文章引用:夏雨桐, 王敏. 基于“邪伏肠络”理论探讨结直肠炎癌转化的动态演变机制及治疗思路[J]. 中医学, 2026, 15(10): 213-220. https://doi.org/10.12677/tcm.2026.1510546

参考文献

[1] 金天, 朱应双, 刘成成, 等. 早发性结直肠癌的流行病学特征分析: 基于单中心前瞻性队列研究[J]. 中华胃肠外科杂志, 2024, 27(5): 457-463.
[2] 田田, 高雪琴, 王榕榕. 1992-2021年中美两国结直肠癌死亡趋势的年龄-时期-队列模型及分解分析[J]. 护理研究, 2026, 40(1): 21-26.
[3] 王倩, 袁江, 刘倩希, 等. 中医药干预结直肠癌免疫逃逸的机制及临床应用的研究进展[J]. 天津中医药, 2025, 42(8): 1079-1088.
[4] 刘运泽, 郑浩呈, 李园, 等. 基于“邪伏肠络”理论探讨结直肠“炎癌转化”的动态演变机制及治疗思路[J]. 北京中医药大学学报, 2024, 47(10): 1343-1348.
[5] 李钟琳, 李玉, 贾晓薇, 等. 从伏毒理论探析应用风药治疗结直肠癌[J]. 湖南中医药大学学报, 2024, 44(11): 2116-2120.
[6] 谭愉琴, 汪紫琪, 杨家翔, 等. 基于伏邪理论探讨结直肠“炎癌转化”的机制及治疗思路[J]. 湖南中医杂志, 2025, 41(8): 129-132.
[7] 魏小曼, 李柳, 程海波. 结直肠癌前病变中医病机探讨[J]. 南京中医药大学学报, 2021, 37(3): 348-351.
[8] 沈洪, 邢敬, 胡静怡, 等. 溃疡性结肠炎“炎-癌”转化的中医药防治策略[J]. 中国中西医结合消化杂志, 2024, 32(5): 379-384.
[9] 赵正奇, 梁玮钰, 杨楚琪, 等. 从“瘀毒互结”探讨结直肠癌的病机特点和治疗[J]. 北京中医药大学学报, 2023, 46(6): 869-873.
[10] 王若冲, 王斌诗, 刘昱慧, 等. 结肠炎相关结直肠癌小鼠模型的中医证候动态探究[J]. 北京中医药大学学报, 2026, 49(2): 231-244.
[11] 吴佳禾, 崔慕瑶, 陈雪, 等. 基于寒气生积探讨炎症性肠病炎-癌转化辨治思路[J]. 中医杂志, 2025, 66(14): 1489-1494.
[12] 崔正易, 闫珺, 刘松江. 基于伏邪理论探讨溃疡性结肠炎相关结肠癌的发病机制[J]. 中国中医基础医学杂志, 2021, 27(11): 1715-1716, 1773.
[13] 谷珍珍, 周芮, 吴娇, 等. 基于“癌毒伏邪”理论探讨结直肠癌复发转移[J]. 中国中医药信息杂志, 2023, 30(11): 20-24.
[14] 吴娇, 李中玉, 吴煜. 基于“伏邪”探讨结直肠癌的复发转移[J]. 吉林中医药, 2023, 43(6): 636-639.
[15] 李玉, 李城, 时浩洋, 等. 基于“伏毒”学说审因论治结直肠癌[J]. 天津中医药, 2024, 41(6): 714-718.
[16] 祖玥, 肖颖媚, 戴玲玲. 侯爱画从虚、浊、瘀、毒论治结直肠癌经验[J]. 长春中医药大学学报, 2024, 40(12): 1325-1329.
[17] 王轶颖, 孙青, 石劲敏, 等. 陈熠运用调神解郁法治疗结直肠癌经验探析[J]. 中医肿瘤学杂志, 2025, 7(6): 114-119.
[18] 王静, 唐泊文, 宋囡, 等. 健脾益气法治疗结直肠癌研究进展[J]. 陕西中医, 2025, 46(3): 420-423.
[19] 潘瑜凡, 王微, 王荣桂. 温阳补肾、活血通络外治法治疗大肠癌术后经奥沙利铂化疗致神经毒性的疗效观察[J]. 江西中医药大学学报, 2022, 34(4): 53-55.
[20] 但春稂, 何金秀, 张旭丽, 等. 吴文尧用清肝健脾化痰散结法治疗胆囊息肉经验[J]. 实用中医药杂志, 2025, 41(1): 193-194.
[21] 尹思源, 叶丽红. 叶丽红教授治疗结直肠癌的临床经验[J]. 浙江中医药大学学报, 2022, 46(9): 993-996.
[22] 祝利民, 史海霞, 徐振晔. 徐振晔教授中医药辨证论治大肠癌的临床数据挖掘[J]. 世界科学技术-中医药现代化, 2021, 23(6): 1773-1783.
[23] Ungaro, R., Mehandru, S., Allen, P.B., Peyrin-Biroulet, L. and Colombel, J. (2017) Ulcerative Colitis. The Lancet, 389, 1756-1770.
https://doi.org/10.1016/s0140-6736(16)32126-2
[24] 中国中西医结合学会消化内镜学专业委员会大肠早癌专家委员会. 结直肠腺瘤及早期结直肠癌中西医结合诊治专家共识(2021) [J]. 中医杂志, 2022, 63(10): 989-997.
[25] Lu, H., Hu, X., Chen, Y. and He, J. (2026) Colorectal Cancer in Ulcerative Colitis: Unraveling Mechanisms and Advancing Surveillance and Chemoprevention. Frontiers in Oncology, 16, Article ID: 1793470.
https://doi.org/10.3389/fonc.2026.1793470
[26] Ni, M., Zhang, Y., Sun, Z., Zhou, Q., Xiao, J., Zhang, B., et al. (2024) Efficacy and Safety of Shenbai Granules for Recurrent Colorectal Adenoma: A Multicenter Randomized Controlled Trial. Phytomedicine, 127, Article ID: 155496.
https://doi.org/10.1016/j.phymed.2024.155496
[27] He, Q., Chen, X., Zeng, H., Gao, X., Zheng, Z., Rao, J., et al. (2026) Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant to Postoperative Chemotherapy in Colorectal Cancer: A Meta-Analysis. Frontiers in Oncology, 15, Article ID: 1700525.
https://doi.org/10.3389/fonc.2025.1700525